A Phase IIb , Placebo-Controlled ,Multi-Center, Randomized, Double-Blind, Dose-explorating Trial of RC18,a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Systemic Lupus Erythematosus (SLE).
Phase of Trial: Phase II
Latest Information Update: 16 Apr 2018
At a glance
- Drugs RC 18 (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors RemeGen
- 11 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 11 Apr 2018 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2019.
- 10 Jun 2017 Biomarkers information updated